Hu Qin, Xiao Ping, Li Junjie, Yu Pijun
Department of Plastic Surgery, Eighth People's Hospital of Shanghai, Shanghai, China.
J Cancer Res Ther. 2016 Jan-Mar;12(1):117-20. doi: 10.4103/0973-1482.151424.
This paper discusses the retrospective analysis conducted to determine the significance of diagnostic biomarkers, carcinoembryonic antigens (CEA), cytokeratin fragment antigens 21-1 (CYFRA 21-1), neuron-specific enolases (NSE), and tumor-specific growth factors (TSGF) upon patients who suffered with non-small cell lung cancer (NSCLC).
From June 2010 to December 2011, we analyzed the positive rates of biomarkers in 276 NSCLC patients. We assessed the relationship between biomarkers and clinical characteristics of sex, smoking history, and disease stage.
The median and positive rates of each serum biomarker were marked as 1.91-22.77 ng/ml and 35.86% (CEA), 2.0-6.77 ng/ml and 50% (CYFRA 21-1), 13.91-23.78 ng/ml and 62.31% (NSE), and 56-67 μ/ml and 10.14% (TSGF). The level of CEA in peripheral (2.43-23.76 ng/ml) was significantly higher than the level at central position (1.97-3.63 ng/ml) (P < 0.05).
Although the positive CEA, CYFRA 21-1, NSE, and TSGF rates were observed at low values during the NSLCLC serum diagnosis, they still played an important role in diagnosing lung cancer. Significant levels of CEA, CYFRA 21-1, NSE, and TSGF were detected in the serum. The amounts found were useful for diagnosing NSCLC patients who depended on the currently limited biomarker development.
本文探讨了一项回顾性分析，以确定诊断生物标志物癌胚抗原（CEA）、细胞角蛋白片段抗原21-1（CYFRA 21-1）、神经元特异性烯醇化酶（NSE）和肿瘤特异性生长因子（TSGF）对非小细胞肺癌（NSCLC）患者的意义。
2010年6月至2011年12月，我们分析了276例NSCLC患者生物标志物的阳性率。我们评估了生物标志物与性别、吸烟史和疾病分期等临床特征之间的关系。
每种血清生物标志物的中位数和阳性率分别为1.91 - 22.77 ng/ml和35.86%（CEA）、2.0 - 6.77 ng/ml和50%（CYFRA 21-1）、13.91 - 23.78 ng/ml和62.31%（NSE）、56 - 67 μ/ml和10.14%（TSGF）。外周血中CEA水平（2.43 - 23.76 ng/ml）显著高于中央位置的水平（1.97 - 3.63 ng/ml）（P < 0.05）。
虽然在NSLCLC血清诊断中观察到CEA、CYFRA 21-1、NSE和TSGF的阳性率较低，但它们在肺癌诊断中仍发挥着重要作用。血清中检测到显著水平的CEA、CYFRA 21-1、NSE和TSGF。所发现的含量对于诊断依赖当前有限生物标志物发展的NSCLC患者很有用。
